Followers | 260 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Sunday, September 21, 2014 3:29:03 PM
That immunity against all types MAY BE incomplete does not negate that EbolaCide SHOULD BE effective against ALL TYPES of Ebola as a treatment. Again, it is not a vaccine, but it in theory should have the effect of a vaccine in stimulating the immune system to produce sufficient antibodies to be effective later. The antibodies produced against a wild virus type should be of broader spectrum than those produced by either attenuated or dead virus vaccines as well as nucleic acid or toxoid based vaccines.
There is one more use for EbolaCide that I believe is not an option for other treatments, and that is its use prophylactically. If it proves effective in the wild and in use against human Ebola infections, then it can be administered as a preventive to people in the community around the outbreak cluster or to the communities on the leading edge of the outbreak areas.
One more thing, "However, if the live virus causes the immune response, the antibodies produced can be broader spectrum" is not made up. Wild viruses have all their active attachment points attenuated and dead viruses have those points reduced. A challenge of the Ebola virus in particular is that attenuated and dead viruses don't operate in the same way. You should already know about the drawbacks of neucleic acid and toxoid based vaccines, especially regarding Ebola and its many strategies for defeating immune response.
“It is difficult to get a man to understand something, when his salary depends on his not understanding it.”
-- Upton Sinclair
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM